BioSpace News Archive

NVision Imaging, a developer of MRI polarizers and hyperpolarized imaging agents, announced that they have closed a $30M Series A round, with an additional $19.5M in funding from the German government.

Hospital for Special Surgery announced its phased leadership transition will be completed on September 5, when Bryan T. Kelly, MD, MBA succeeds Louis A. Shapiro as CEO.

Results of a Phase III randomized clinical trial published in the New England Journal of Medicine indicates that a new strategy for prevention of graft versus host disease for blood cancer patients receiving allogeneic hematopoietic cell transplantation from well-matched donors significantly improves GVHD-free/relapse -free survival.

Just two months after announcing the world’s first positive surgical trial for the deadliest type of stroke, NICO Corporation is awarding a $200,000 Investigator Initiated Study grant with the goal of building on ENRICH (Early MiNimally-invasive Removal of ICH) conclusions to further improve patient outcomes following hemorrhagic stroke.

The American Diabetes Association® announced that it has received a $12.5 million grant from the Centers for Disease Control and Prevention to build upon the CDC’s National Diabetes Prevention Program.

Cognigenics CEO John L. Mee announces breakthrough results from an animal study published in PNAS Nexus.

The American Academy of Dermatology is launching an innovative breakthrough project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients suffering from generalized pustular psoriasis, a rare form of psoriasis that causes widespread, pus-filled blisters, called pustules.

Erasca, Inc. (Nasdaq: ERAS) today announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ERAS-801 for the treatment of malignant glioma, which includes glioblastoma (GBM).

Moderna, Inc. (NASDAQ:MRNA) today announced that it has completed submission of a regulatory application to the U.S. Food and Drug Administration for its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 (mRNA-1273.815).

Daxor Corporation announced that Maxim Group LLC, as Representative of several Underwriters of its previously announced secondary public offering have partially exercised their option to purchase an additional 54,339 Option Shares of Daxor’s Class A common stock at a public price of $9.75 per share.